Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) achieved a 14% increase in annual revenues, reaching $732 million for the 2024 fiscal year. The company recorded a solid 5% year-over-year growth in the ...

Over the past 90 days, revenue estimates for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) have declined from $737.66 million to $734.23 million for the full year 2024 and from $806.58 million to $ ...

In this article, we are going to take a look at where Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) stands against the other ...

Today, we are looking at generic pharmaceuticals stocks, starting with Amphastar Pharmaceuticals (NASDAQ:AMPH). The generic ...

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season. The generic ...

Today, we are looking at generic pharmaceuticals stocks, starting with Amphastar Pharmaceuticals (NASDAQ:AMPH). The generic pharmaceutical industry operates on a volume-driven, low-cost business model ...

("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter ...